JP2022544559A5 - - Google Patents
Info
- Publication number
- JP2022544559A5 JP2022544559A5 JP2022509131A JP2022509131A JP2022544559A5 JP 2022544559 A5 JP2022544559 A5 JP 2022544559A5 JP 2022509131 A JP2022509131 A JP 2022509131A JP 2022509131 A JP2022509131 A JP 2022509131A JP 2022544559 A5 JP2022544559 A5 JP 2022544559A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- compound
- pharmaceutical composition
- pharmaceutically acceptable
- human subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962886621P | 2019-08-14 | 2019-08-14 | |
| US62/886,621 | 2019-08-14 | ||
| US201962946774P | 2019-12-11 | 2019-12-11 | |
| US62/946,774 | 2019-12-11 | ||
| PCT/US2020/046329 WO2021030671A1 (en) | 2019-08-14 | 2020-08-14 | Tetracyclic compounds and their salts, compositions, and methods for their use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022544559A JP2022544559A (ja) | 2022-10-19 |
| JP2022544559A5 true JP2022544559A5 (enExample) | 2023-08-22 |
| JP7566010B2 JP7566010B2 (ja) | 2024-10-11 |
Family
ID=74568302
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022509131A Active JP7566010B2 (ja) | 2019-08-14 | 2020-08-14 | 四環式化合物及びそれらの塩、組成物、ならびにそれらの使用方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20210046071A1 (enExample) |
| EP (1) | EP4013421A4 (enExample) |
| JP (1) | JP7566010B2 (enExample) |
| KR (1) | KR20220130085A (enExample) |
| CN (1) | CN114599368A (enExample) |
| AU (1) | AU2020328590B2 (enExample) |
| BR (1) | BR112022002784A2 (enExample) |
| CA (1) | CA3151112A1 (enExample) |
| IL (1) | IL290626A (enExample) |
| PH (1) | PH12022550360A1 (enExample) |
| TW (1) | TW202114694A (enExample) |
| WO (1) | WO2021030671A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119185322A (zh) | 2015-11-20 | 2024-12-27 | 生华生物科技股份有限公司 | 用于治疗癌症的四环喹诺酮类似物组合疗法 |
| EP3752149A4 (en) | 2018-02-15 | 2022-03-02 | Senhwa Biosciences, Inc. | QUINOLONE ANALOGUES AND THEIR SALTS, COMPOSITIONS AND METHODS OF USE |
| CN114409681A (zh) * | 2022-03-18 | 2022-04-29 | 信义核新(北京)生物科技有限公司 | 用于治疗dna损伤修复缺陷肿瘤的喹诺酮类似物及其应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101601332B1 (ko) * | 2007-10-05 | 2016-03-08 | 센화 바이오사이언시즈 인코포레이티드 | 퀴놀론 유사체 및 이와 관련된 방법 |
| US8853235B2 (en) * | 2009-11-23 | 2014-10-07 | Senhwa Biosciences, Inc. | Polymorphs and salts of a kinase inhibitor |
| EP3074391B1 (en) * | 2013-11-28 | 2019-07-31 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Rna polymerase i inhibitors and uses thereof |
| CN119185322A (zh) * | 2015-11-20 | 2024-12-27 | 生华生物科技股份有限公司 | 用于治疗癌症的四环喹诺酮类似物组合疗法 |
| ES2959536T3 (es) | 2015-12-14 | 2024-02-26 | Senhwa Biosciences Inc | Formas cristalinas de análogos de quinolona y sus sales |
| US9957282B2 (en) * | 2015-12-14 | 2018-05-01 | Senhwa Biosciences, Inc. | Crystalline forms of quinolone analogs and their salts |
| EP3752149A4 (en) * | 2018-02-15 | 2022-03-02 | Senhwa Biosciences, Inc. | QUINOLONE ANALOGUES AND THEIR SALTS, COMPOSITIONS AND METHODS OF USE |
-
2020
- 2020-08-14 US US16/993,840 patent/US20210046071A1/en active Pending
- 2020-08-14 EP EP20851932.2A patent/EP4013421A4/en active Pending
- 2020-08-14 WO PCT/US2020/046329 patent/WO2021030671A1/en not_active Ceased
- 2020-08-14 PH PH1/2022/550360A patent/PH12022550360A1/en unknown
- 2020-08-14 AU AU2020328590A patent/AU2020328590B2/en active Active
- 2020-08-14 KR KR1020227008247A patent/KR20220130085A/ko not_active Withdrawn
- 2020-08-14 JP JP2022509131A patent/JP7566010B2/ja active Active
- 2020-08-14 TW TW109127804A patent/TW202114694A/zh unknown
- 2020-08-14 CA CA3151112A patent/CA3151112A1/en active Pending
- 2020-08-14 BR BR112022002784A patent/BR112022002784A2/pt not_active Application Discontinuation
- 2020-08-14 CN CN202080069508.0A patent/CN114599368A/zh active Pending
-
2022
- 2022-02-14 IL IL290626A patent/IL290626A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7492002B2 (ja) | Ｌｓｄ１阻害剤によりｌｓｄ１関連疾患及び障害を治療する方法 | |
| WO2024088273A1 (zh) | 一种萘酰胺化合物治疗kras突变相关疾病的用途 | |
| JP2022121594A5 (enExample) | ||
| JP2006523216A5 (enExample) | ||
| JP2010189446A (ja) | 肝臓癌の発症予防のための医薬 | |
| JP2022502450A5 (enExample) | ||
| JP2025098190A5 (enExample) | ||
| SE462076B (sv) | Antitoemoerkomposition innehaallande diltiazem och ett antitoemoermedel som utvaeljs bland vincristin och doxorubicin, samt anvaendning av diltiazem foer framstaellning av ett antitumoermedel med potentierad verkan | |
| CN120713908A (zh) | 帕布昔利布在黏膜恶性黑色素瘤中的应用 | |
| JP2013523867A5 (enExample) | ||
| JP5210888B2 (ja) | 黒色腫の治療のためのガリウム（ｉｉｉ）錯体の使用 | |
| JP2022502378A5 (enExample) | ||
| JP7357386B2 (ja) | 化合物又はその薬学的に許容される塩、二量体又は三量体のがん治療用医薬品の調製における応用 | |
| US20200237779A1 (en) | Combination therapy with a bet inhibitor and a bcl-2 inhibitor | |
| JPWO1992004028A1 (ja) | 抗腫瘍効果増強剤及び抗腫瘍剤 | |
| CN114173779A (zh) | 对抗ccr4抗体具有抗性的癌症的治疗剂 | |
| WO2024160057A1 (zh) | 长效β2AR激动剂在制备治疗癌症药物中的应用 | |
| JP5570429B2 (ja) | デオキシシチジン誘導体を含有する抗腫瘍剤を投与する方法 | |
| WO2020045461A1 (ja) | ピラゾロ［３，４－ｄ］ピリミジン化合物を有効成分とする治療剤 | |
| JP5578753B2 (ja) | 抗腫瘍効果増強剤、抗腫瘍剤及び癌治療方法 | |
| WO1997024126A1 (en) | Malignant tumor metastasis inhibitors | |
| JP2024515100A5 (enExample) | ||
| CN109481687B (zh) | 用于胃癌治疗的cdk4/6抑制剂联合her2抑制剂的组合 | |
| RU2022106182A (ru) | Тетрациклические соединения и их соли, составы и способы их применения | |
| JP2022551105A5 (enExample) |